本文選題：骨質(zhì)疏松 + 椎體成形術(shù)　； 參考：《中國骨質(zhì)疏松雜志》2017年05期

【摘要】：目的評(píng)價(jià)補(bǔ)腎健脾中藥復(fù)方對(duì)骨質(zhì)疏松性椎體骨折椎體成形術(shù)后再骨折的預(yù)防作用。方法 92例因骨質(zhì)疏松性椎體骨折而行椎體成形術(shù)的患者隨機(jī)分為觀察組和對(duì)照組,每組46例。所有患者進(jìn)行12月隨訪,期間記錄患者出院時(shí)、術(shù)后3個(gè)月、末次隨訪的骨密度情況和椎體骨折情況,并采用Oswestry功能障礙指數(shù)分記錄患者功能情況。結(jié)果最終納入統(tǒng)計(jì)的患者85例,其中觀察組43例和對(duì)照組42例。在骨密度方面,觀察組腰椎和髖部骨密度呈上升趨勢(shì),對(duì)照組的骨密度呈下降趨勢(shì),而且腰椎和髖部的末次隨訪的骨密度與出院時(shí)比較,其差異有統(tǒng)計(jì)學(xué)意義(P0.05)。觀察組和對(duì)照組在術(shù)后3個(gè)月髖部骨密度方面,差異有統(tǒng)計(jì)學(xué)意義(P0.05),兩者在末次隨訪時(shí)腰椎骨密度和髖部骨密度比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。在椎體是否再發(fā)骨折方面,在末次隨訪時(shí),觀察組有2例骨折,對(duì)照組有8例骨折,經(jīng)比較,兩者差異有統(tǒng)計(jì)學(xué)意義(P0.05)。在功能改善方面,觀察組在術(shù)后3個(gè)月和末次隨訪時(shí)的功能優(yōu)于對(duì)照組,其差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論補(bǔ)腎健脾中藥復(fù)方能提高骨密度,有效維持骨密度的變化,降低椎體再骨折的風(fēng)險(xiǎn),而且能明顯改善患者術(shù)后的功能和癥狀。
[Abstract]:Objective to evaluate the preventive effect of tonifying kidney and invigorating spleen compound on vertebral refracture after vertebroplasty for osteoporotic vertebral fracture. Methods 92 patients with osteoporotic vertebral fracture were randomly divided into observation group (n = 46) and control group (n = 46). All patients were followed up for 12 months. The bone mineral density (BMD) and vertebral fracture were recorded at the time of discharge, 3 months after operation and the last follow-up. The functional status of patients was recorded by Oswestry dysfunction index. Results 85 patients were included in the statistics, including 43 cases in the observation group and 42 cases in the control group. In terms of BMD, the BMD of lumbar vertebrae and hip showed an upward trend in the observation group, and the BMD of the control group decreased, and the BMD of the last follow-up of the lumbar vertebrae and hip was significantly higher than that of the discharged patients (P 0.05). There was a significant difference in bone mineral density of hip between the observation group and the control group at 3 months after operation (P 0.05), and the difference between the two groups at the last follow-up was significant (P 0.05). At the last follow-up, there were 2 cases of fracture in the observation group and 8 cases in the control group. The difference between the two groups was statistically significant (P 0.05). In terms of functional improvement, the function of the observation group was better than that of the control group at 3 months and the last follow-up, and the difference was statistically significant (P 0.05). Conclusion the compound prescription of tonifying kidney and invigorating spleen can increase BMD, maintain the change of BMD, reduce the risk of vertebral refracture, and improve the function and symptoms of patients after operation.
【作者單位】： 廣東省中西醫(yī)結(jié)合醫(yī)院;廣州中醫(yī)藥大學(xué);
【基金】：廣州市珠江科技新星項(xiàng)目(2012J2200037) 佛山市科技創(chuàng)新平臺(tái)建設(shè)項(xiàng)目(2013AG100022)
【分類號(hào)】：R274.9

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 葉朝輝;韓軍偉;代根奇;;椎體成形術(shù)配合中醫(yī)藥辨證治療老年性椎體壓縮性骨折[J];中國民族民間醫(yī)藥;2013年09期

2 宓士軍;高萬旭;周廣軍;田小芳;孫敬宇;付靜波;;復(fù)方接骨膠囊對(duì)胸腰椎骨質(zhì)疏松骨折椎體成形術(shù)后的影響[J];中華中醫(yī)藥雜志;2009年10期

3 孟春;胡柏松;倪曉亮;;宧薟狗脊延胡湯為主治療椎體成形術(shù)后殘留腰背痛[J];中醫(yī)正骨;2010年04期

4 ;[J];;年期

，

本文編號(hào)：1819652